Heron Therapeutics, Inc.
HRTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $233,247 | $234,830 | $272,491 | $899,040 |
| - Cash | $25,802 | $28,677 | $15,364 | $90,541 |
| + Debt | $177,763 | $179,628 | $157,477 | $159,495 |
| Enterprise Value | $385,208 | $385,781 | $414,604 | $967,994 |
| Revenue | $144,285 | $127,044 | $107,672 | $86,346 |
| % Growth | 13.6% | 18% | 24.7% | – |
| Gross Profit | $105,637 | $61,939 | $52,798 | $40,325 |
| % Margin | 73.2% | 48.8% | 49% | 46.7% |
| EBITDA | -$5,056 | -$103,792 | -$176,661 | -$215,252 |
| % Margin | -3.5% | -81.7% | -164.1% | -249.3% |
| Net Income | -$13,580 | -$110,559 | -$182,024 | -$220,683 |
| % Margin | -9.4% | -87% | -169.1% | -255.6% |
| EPS Diluted | -0.089 | -0.8 | -1.67 | -2.24 |
| % Growth | 88.9% | 52.1% | 25.4% | – |
| Operating Cash Flow | -$22,529 | -$58,789 | -$146,912 | -$203,354 |
| Capital Expenditures | -$1,706 | -$1,545 | -$1,825 | -$3,022 |
| Free Cash Flow | -$24,235 | -$60,334 | -$148,737 | -$206,376 |